Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 7/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16202039 | 0.81 | ALDH1A1 (0.40) | ALDH1A1NPC1NOTUMMEN1KMT2A | |
| SCHEMBL28330107 | 0.76 | CYP2C9 (0.40) | ALDH1A1NPC1GAAMAPT | |
| SCHEMBL16202041 | 0.74 | ALDH1A1 (0.38) | ALDH1A1NPC1NOTUMMEN1KMT2A | |
| SCHEMBL24051565 | 0.73 | RXRA (0.35) | ALDH1A1RXRAGRIN1GRIN2BKMT2A | |
| SCHEMBL15984869 | 0.73 | HTT (0.50) | ALDH1A1NPC1NOTUMMEN1KMT2A | |
| SCHEMBL15980626 | 0.71 | NOTUM (0.40) | ALDH1A1NPC1NOTUMMEN1KMT2A | |
| SCHEMBL16202042 | 0.71 | MAPT (0.52) | ALDH1A1NPC1NOTUMMEN1KMT2A | |
| SCHEMBL44771 | 0.70 | ALDH1A1 (0.49) | ALDH1A1NPC1NOTUMMEN1KMT2A | |
| SCHEMBL19119906 | 0.68 | GRM5 (0.38) | GRIN1GRIN2B | |
| SCHEMBL6819010 | 0.68 | KMT2A (0.36) | RXRAGRIN1GRIN2BKMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9271501-B2 | Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors | BASF SE (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | BASF SE (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | SQOR, COX5B, UQCRB | ALDH1A1 2278/4885NPC1 601/4885NOTUM 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.